Matches in Nanopublications for { ?s ?p ?o <http://bio2rdf.org/drugbank:DB01151_nanopub.RAR5XzOe6Rvy4XE7tsji9V3CWhPJ4taJUNLEGZaXxesCw#assertion>. }
Showing items 1 to 32 of
32
with 100 items per page.
- drugbank:DB01151 type drugbank_vocabulary:Drug assertion.
- drugbank:DB01151 label "Desipramine [drugbank:DB01151]" assertion.
- drugbank:DB01151 seeAlso DB01151 assertion.
- drugbank:DB01151 seeAlso desipramine.html assertion.
- drugbank:DB01151 seeAlso desipram.htm assertion.
- drugbank:DB01151 identifier "drugbank:DB01151" assertion.
- drugbank:DB01151 description "Desipramine hydrochloride is a dibenzazepine-derivative tricyclic antidepressant (TCA). TCAs are structurally similar to phenothiazines. They contain a tricyclic ring system with an alkyl amine substituent on the central ring. In non-depressed individuals, desipramine does not affect mood or arousal, but may cause sedation. In depressed individuals, desipramine exerts a positive effect on mood. TCAs are potent inhibitors of serotonin and norepinephrine reuptake. Secondary amine TCAs, such as desipramine and nortriptyline, are more potent inhibitors of norepinephrine reuptake than tertiary amine TCAs, such as amitriptyline and doxepine. TCAs also down-regulate cerebral cortical β-adrenergic receptors and sensitize post-synaptic serotonergic receptors with chronic use. The antidepressant effects of TCAs are thought to be due to an overall increase in serotonergic neurotransmission. TCAs also block histamine-H<sub>1</sub> receptors, α<sub>1</sub>-adrenergic receptors and muscarinic receptors, which accounts for their sedative, hypotensive and anticholinergic effects (e.g. blurred vision, dry mouth, constipation, urinary retention), respectively. See toxicity section below for a complete listing of side effects. Desipramine exerts less anticholinergic and sedative side effects compared to tertiary amine TCAs, such as amitriptyline and clomipramine. Desipramine may be used to treat depression, neuropathic pain (unlabeled use), agitation and insomnia (unlabeled use) and attention-deficit hyperactivity disorder (unlabeled use)." assertion.
- drugbank:DB01151 title "Desipramine" assertion.
- drugbank:DB01151 bio2rdf_vocabulary:identifier "DB01151" assertion.
- drugbank:DB01151 bio2rdf_vocabulary:namespace "drugbank" assertion.
- drugbank:DB01151 bio2rdf_vocabulary:uri "http://bio2rdf.org/drugbank:DB01151" assertion.
- drugbank:DB01151 bio2rdf_vocabulary:x-identifiers.org DB01151 assertion.
- drugbank:DB01151 drugbank_vocabulary:drugbank-id "APRD00022" assertion.
- drugbank:DB01151 drugbank_vocabulary:drugbank-id "DB01151" assertion.
- drugbank:DB01151 drugbank_vocabulary:drugbank-id "DB07682" assertion.
- drugbank:DB01151 drugbank_vocabulary:x-cas cas:50-47-5 assertion.
- drugbank:DB01151 drugbank_vocabulary:x-chemspider chemspider:2888 assertion.
- drugbank:DB01151 drugbank_vocabulary:x-pdb pdb:DSM assertion.
- drugbank:DB01151 drugbank_vocabulary:x-pubchemcompound pubchem.compound:2995 assertion.
- drugbank:DB01151 drugbank_vocabulary:x-pubchemsubstance pubchem.substance:46504624 assertion.
- drugbank:DB01151 drugbank_vocabulary:x-ahfs ahfs:28:16.04.28 assertion.
- drugbank:DB01151 drugbank_vocabulary:x-atc atc:N06AA01 assertion.
- drugbank:DB01151 drugbank_vocabulary:x-chebi chebi:47781 assertion.
- drugbank:DB01151 drugbank_vocabulary:x-dpd dpd:2216272 assertion.
- drugbank:DB01151 drugbank_vocabulary:x-kegg kegg:C06943 assertion.
- drugbank:DB01151 drugbank_vocabulary:x-kegg kegg:D07791 assertion.
- drugbank:DB01151 drugbank_vocabulary:x-pharmgkb pharmgkb:PA449233 assertion.
- drugbank:DB01151 drugbank_vocabulary:x-wikipedia wikipedia:Desipramine assertion.
- drugbank:DB01151 drugbank_vocabulary:x-bindingdb bindingdb:35229 assertion.
- drugbank:DB01151 drugbank_vocabulary:x-ndc ndc:0781-1971-01 assertion.
- drugbank:DB01151 drugbank_vocabulary:x-gtp gtp:2399 assertion.
- drugbank:DB01151 drugbank_vocabulary:x-iuphar iuphar:2399 assertion.